Competition in long-acting schizophrenia injections between Otsuka and Janssen
When it comes to treating schizophrenia, competition among long-acting injections(LAIs) is about to be intensified.
This is because a series of new drug launches are expected for schizophrenia patients who are having difficulties in constant management of the disease.
According to the industr...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
